Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39591—Stabilisation, fragmentation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Definitions

• the invention is directed to stable, concentrated formulations of proteins or antibodies, such as natalizumab, wherein the activity of the antibody is retained and also can be administered in a small volume and can be administered to a subject of variable weight in need thereof.
• Antibody and protein formulations are known in the art.
• preparing protein formulations, such as antibody formulations, which are chemically and biologically stable are fraught with challenges.
• Preparing formulations which are also not only stable but can maintain a small volume (i.e., allowing for a small volume injection) even with an increased concentration of protein, such as antibody also is problematic.
• the need for such formulations exist.
• concentrated amounts of protein in a fixed volume that is also stable would be especially beneficial to patients of variable weight.
• Administration of fluids to patients of variable weights may, for example, have an adverse reaction. Development of such formulations has been hindered by the proteins or the antibodies themselves, which have a high tendency to aggregate and precipitate.
• One aspect of the invention provides for a stable, aqueous pharmaceutical formulation comprising an immunoglobulin (or other protein), a phosphate buffer, a polysorbate, and sodium chloride.
• the polysorbate is polysorbate 80, and preferably in the amount of about 0.001% to about 2.0% (w/v). Most preferably the polysorbate is present in the amount of about 0.02%.
• the immunoglobulin or other protein is present in the formulation in an amount of about 0.1 mg/mL to about 200 mg/mL.
• the formulation is buffered to a pH between about 3.0 and about 7.0 and most preferably is about 6.0 ⁇ 0.5.
• the formulation is preferably isotonic.
• the formulation may further comprise histidine.
• the histidine is L-histidine.
• the immunoglobulin of the above formulation is an anti-alpha-4 integrin antibody, such as natalizumab or another humanized antibody or monoclonal antibody.
• This antibody can be present in a standard amount or in a concentrated amount, e.g., about 15 mg/mL or more.
• the natalizumab is present in an amount from about 20 mg/mL to about 150 mg/mL. In instances wherein the formulation is present in a concentration of about 15 mg/mL or more, this formulation is maintained in a fixed volume, for example, of about 125 mL.
• It is a further object of the invention to provide a method of treating a patient with variable weight for a condition with a therapeutic amount of an immunoglobulin comprising administering a formulation as described above and herein, wherein the condition is treated by administration of the formulation.
• the condition be one that is mediated by alpha-4 integrin, and in such conditions the immunoglobulin is one which recognizes and binds to alpha-4 integrin, such as natalizumab.
• a further aspect of the invention provides for a composition
• a composition comprising a sodium phosphate, a polysorbate, a protein and NaCl with a pH of 6.0 ⁇ 0.5, wherein the composition is stable when stored at 5° C. to 8° C. for a long period of time.
• Another aspect of the invention provides for a method of preparing a stable protein containing formulation comprising admixing sodium phosphate, sodium chloride, a polysorbate and a protein and adjusting the pH of the mixture with phosphoric acid to about pH 6.0 ⁇ 0.5.
• the protein may be lyophilized in the formulation of the present invention.
• the polysorbate is preferably polysorbate 80 k, present in an amount of about 0.02% (w/v), and the protein is preferably natalizumab.
• the formulation may further comprise histidine.
• the protein is lyophilized in a solution comprising 5 mM histidine, 20 mg/mL sucrose and 0.02% polysorbate 80 at a pH 6, and the protein is natalizumab at a concentration of 20 mg/mL.
• Another aspect of the invention provides for a method for treating a patient with variable weight for a condition, comprising simultaneously or sequentially administering to the patient a therapeutically effective combination of a formulation described above and herein and a compound or therapy effective against the condition.
• This medicament may further comprise a second compound or therapy to treat the condition.
• protein is meant to include but is not limited to immunoglobulins, enzymes, receptor, and fragments thereof. Although discussion of the formulation is provided mainly in reference to an antibody or immunoglobulin, other proteins are contemplated as interchangeable in the formulations disclosed.
• immunoglobulin is meant to include but is not limited to an antibody and antibody fragment (such as scFv, Fab, Fc, F(ab′) 2 ), and other genetically engineered portions of antibodies.
• antibody and antibody fragment such as scFv, Fab, Fc, F(ab′) 2
• immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM. Several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, and IgG4; IgA1 and IgA2.
• the heavy chain constant domains that correspond to the different classes of immunoglobulins are called alpha ( ⁇ ), delta ( ⁇ ), epsilon ( ⁇ ), gamma ( ⁇ ), and mu ( ⁇ ), respectively.
• the subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.
• the immunoglobulin recognizes and binds to alpha-4 integrin.
• antibody is used in the broadest sense and specifically covers monoclonal antibodies (including agonist and antagonist antibodies), antibody compositions with polyepitopic specificity, and antibody fragments (e.g., Fab, F(ab′) 2 , scFv and Fv), so long as they exhibit the desired biological activity. “Antibody” is meant to include polyclonal antibodies, monoclonal antibodies, humanized antibodies, human antibodies, primatized® antibodies and other antibodies produced via genetic engineering.
• the term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by mammalian cell expression systems or transgenic technology, uncontaminated by other immunoglobulins.
• the monoclonal antibodies to be used in accordance with the present invention may be expressed in goats, as described by Behboodi, et al. (2002) Transgenic cloned goats and the production of therapeutic proteins . In Principles of Cloning . Elsevier Science (USA); and Meade et al. (1999). Expression of recombinant proteins in the milk of transgenic animals in Gene expression systems: using nature for the art of expression . J. M. Fernandez and J. P. Hoeffler ed., Academic Press.
• the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
• the monoclonal antibodies to be used in accordance with the present invention may be made by the methods described by Shepherd et al., Monoclonal Antibodies: A Practical Approach (Oxford University Press, 2000).
• monoclonal antibodies also includes “chimeric” antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity. For example, the ability to bind to alpha-4 integrin.
• “monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described for example in Clackson et al., 1991 Nature 352: 624-628 and Marks et al., 1991 J. Mol. Biol., 222: 581-597.
• “Humanized” forms of non-human (e.g., murine, rabbit, bovine, equine, porcine, and the like) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′) 2 or other antigen-binding subsequences of antibodies), which contain minimal sequence derived from non-human immunoglobulin.
• humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
• CDR complementary determining region
• donor antibody non-human species
• Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
• humanized antibody may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
• the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
• the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
• linear antibodies are also included by the general term “antibody” and are a pair of tandem Fd segments (VH-CH1-VH -CH1), which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
• a “variant antibody” (also included by the generic term “antibody”) is a molecule which differs in amino acid sequence from a “parent” antibody's amino acid sequence by virtue of addition, deletion and/or substitution of one or more amino acid residue(s) in the parent antibody sequence.
• the variant comprises one or more amino acid substitution(s) in one or more hypervariable region(s) of the parent antibody.
• the variant may comprise at least one substitution, e.g., from about one to about ten, and preferably from about two to about five, in one or more hypervariable regions of the parent antibody.
• the variant will have an amino acid sequence having at least 75% amino acid sequence identity with the parent antibody heavy or light chain variable domain sequences, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95%.
• Identity or homology with respect to this sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the parent antibody residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. None of the N-terminal, C-terminal, or internal extensions, deletions, or insertions into the antibody sequence should be construed as affecting sequence identity or homology.
• the variant antibody of particular interest is one which displays at least about 10 fold, preferably at least about 20 fold, and most preferably at least about 50 fold, enhancement in biological activity when compared to the parent antibody.
• the “parent” antibody is one which is encoded by an amino acid sequence used for the preparation of the variant.
• the parent antibody has a human framework region and has human antibody constant region(s).
• the parent antibody may be a humanized or a human antibody.
• an “isolated antibody” is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
• the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or, preferably, silver stain.
• Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
• Antibody fragments comprise a portion of an intact antibody, generally the antigen binding or variable region of the intact antibody.
• antibody fragments include Fab, Fab′, F(ab′) 2 , and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
• Single-chain Fv or “sFv” antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain.
• the Fv polypeptide further comprises a polypeptide linker between the VH and VH domains which enables the sFv to form the desired structure for antigen binding.
• diabodies refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH-VL).
• VH heavy chain variable domain
• VL light chain variable domain
• the route of antibody administration is in accord with known methods and are well known, and may include, for example, injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, or intralesional routes, or by sustained release systems.
• the antibody can be administered continuously by infusion or by bolus injection.
• Therapeutic antibody compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
• “Pharmaceutically acceptable” excipients e.g., vehicles, additives
• a “stable” formulation is one in which the protein therein essentially retains its physical stability and/or chemical stability and/or biological activity upon storage.
• stable is also meant a formulation which exhibits little or no signs of instability, including aggregation and/or deamidation.
• the formulations provided by the present invention may remain stable for at least two years, when stored as indicated at a temperature of 5-8° C.
• Stability can be measured at a selected temperature for a selected time period as exemplified by the provided examples. Storage of stable formulations if preferably for at least 6 months, more preferably 12 months, more preferably 12-18 months, and more preferably for 2 or more years.
• a protein such as an antibody or fragment thereof, “retains its physical stability” in a pharmaceutical formulation if it shows no signs of aggregation, precipitation, deamidation and/or denaturation upon visual examination of color and/or clarity, or as measured by UV light scattering or by size exclusion chromatography.
• a protein “retains its chemical stability” in a pharmaceutical formulation if the chemical stability at a given time is such that the protein is considered to still retain its biological activity.
• Chemical stability can be assessed by detecting and quantifying chemically altered forms of the protein.
• Chemical alteration may involve size modification (e.g., clipping), which can be evaluated using size exclusion chromatography, SDS-PAGE and/or matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI/TOF MS), for examples.
• Other types of chemical alteration include charge alteration (e.g., occurring as a result of deamidation), which can be evaluated by ion-exchange chromatography, for example.
• An antibody “retains its biological activity” in a pharmaceutical formulation, if the biological activity of the antibody at a given time is within about 10% (within the errors of the assay) of the biological activity exhibited at the time the pharmaceutical formulation was prepared as determined in an antigen binding assay, for example.
• isotonic is meant that the formulation of interest has essentially the same osmotic pressure as human blood. Isotonic formulations will generally have an osmotic pressure from about 250 to 350 mOsm. Isotonicity can be measured using a vapor pressure or ice-freezing type osmometer, for example.
• buffer refers to a buffered solution that resists changes in pH by the action of its acid-base conjugate components.
• the buffer of this invention has a pH in the range from about 3.0 to about 7.5; preferably from about pH 4.0 to about 7.0; more preferably from about pH 5.0 to about 6.5; and most preferably has a pH of about 6.0 ⁇ 0.5.
• a pH of any point in between the above ranges is also contemplated.
• a “therapeutically effective amount” of an antibody refers to an amount effective in the prevention or treatment of a disorder for the treatment of which the antibody is effective.
• a “disorder” is any condition that would benefit from treatment with the antibody or protein. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question.
• Treatment refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.
• a “preservative” is a compound which can be included in the formulation to essentially reduce bacterial action therein, thus facilitating the production of a multi-use formulation, for example.
• potential preservatives include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl groups are long-chain compounds), and benzethonium chloride.
• preservatives include aromatic alcohols such as phenol, butyl and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol.
• patient or “subject” is meant to include any mammal.
• a “mammal,” for purposes of treatment, refers to any animal classified as a mammal, including but not limited to humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, and the like.
• the mammal is human.
• natalizumab is a recombinant, humanized anti-alpha-4 integrin antibody.
• the disease or condition being treated in the mammal is one which is modulated when a therapeutically effective dose of natalizumab is administered.
• stable is meant a formulation which exhibits little or no signs of instability, including aggregation and/or deamidation.
• stable may also refer to a formulation which does not exhibit any signs of instability for greater than or equal to two years, when stored as indicated at
• formulations for stable antibody formulations are disclosed. Certain stable formulations disclosed have high concentrations of antibody but maintain a fixed volume, wherein the antibodies in these formulations are stable and the antibody does not precipitate out of solution or aggregate. Proteins other than antibodies are also contemplated for the high concentration formulations.
• Antibodies are typically administered to a subject (e.g., a human) at a concentration of about 0.01 mg/mL to about 200 mg/mL. More typically, antibodies range in concentration from about 0.1 mg/mL to about 150 mg/mL. However, instances exist when greater concentrations are required to be administered to a patient, e.g., about 15 to about 200 mg/mL, more preferably about 15 mg/mL to 150 mg/mL, more preferably about 20 to about 50 mg/mL, and most preferably about 20 mg/mL and any integer value in between.
• the antibody formulation may be administered to a mammal in need of treatment with the protein, in accordance with known methods. These methods may include, but are not limited to intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerobrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. In preferred embodiments, the antibody formulation is administered to the mammal by intravenous administration.
• the appropriate dosage of the protein will depend, for example, on the condition to be treated, the severity and course of the condition, whether the protein is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the protein, the type of protein used, and the discretion of the attending physician.
• the protein is suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis onwards.
• the protein may be administered as the sole treatment or in conjunction with other drugs or therapies useful in treating the condition in question.
• two (or more) agents are said to be administered in combination when the two agents are administered simultaneously or are administered independently in a fashion such that the agents will act contemporaneously.
• the compounds of this invention may be used alone or in combination, or in combination with other therapeutic agents.
• the compounds of this invention may be co-administered along with other compounds typically prescribed for these conditions according to generally accepted medical practice.
• the formulations of this invention can be administered in combination with other therapeutic agents or physical therapies for the treatment of rheumatoid arthritis, multiple schlerosis and Crohn's Disease.
• the process can be altered as would be known to the skilled artisan, but generally would follow a procedure such as the following.
• Prepare the inoculum. Culture or ferment the cells with additional feedings as is necessary.
• Harvest/clarify the cells by centrifugation and/or filtration. This can be done for example by concentrating the cells 10 fold by spiral wound filtration. Filter by a 0.2 ⁇ m intermediate filtration followed by purification by protein A Sepharose Fast Flow® (i.e., affinity chromatography) and reverse elution.
• the antibody containing composition then receives a treatment at pH 3.6-3.7.
• the mixture receives a viral filtration followed by a concentration/diafiltration step.
• the composition can then be purified by DEAE Sepharose Fast Flow® (anion exchange). This step can be performed multiple times. From this point, the composition is then further concentrated followed by a purification step using Sephacryl S300HR® (i.e., gel filtration chromatography) system, wherein the running buffer used is phosphate/NaCl.
• the antibody containing composition can be further concentrated for the high concentration formulations (e.g., 20 mg/mL or more) if so desired.
• the antibody containing composition is then further buffered and the concentration adjusted by adding 0.02% (w/v) polysorbate 80. This composition then receives a final filtration using a 0.2 ⁇ m filter and can be dispensed at this point into 100 mL to 10 L polypropylene bottles.
• the antibody or immunoglobulin so obtained can then be QC tested and QA released.
• an immunoglobulin is formulated in concentrations of about 1.7, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 40.0 or 50.0 mg/mL in 10 mM sodium phosphate, 140 mM NaCl (pH 6.0 ⁇ 0.5) and 0.02% polysorbate 80. If necessary, the pH is adjusted to 6.0 ⁇ 0.5 with phosphoric acid.
• any of the above formulations are optimally vialed in an aseptic vial.
• These vials can be, for example, Type I EP neutral glass vials (e.g., 5.0 or 20 mL fill vials) with Helvoet Pharma V9145/FM 157/1 gray butyl rubber stoppers with aluminum seals.
• Other suitable aseptic vials are also contemplated.
• the formulations can be bottled as follows: BOTTLING Compounding of phosphate/sodium chloride/polysorbate 80 buffer, if needed ⁇ Sterilization of vials, stoppers and manufacturing equipment ⁇ Dilution with phosphate/sodium chloride/polysorbate 80 buffer antibody to 1.7 or 50 mg/mL, as required ⁇ Sterile filtration ⁇ Aseptic filling and stoppering of vials Capping ⁇ Release Testing
• natalizumab obtained for example by the procedures discussed above can be bottled as follows.
• Natalizumab 200 L and 2000 L drug product can be filled on a fully automated filling line equipped with a vial washing, sterilization and depyrogenation tunnel. Stoppers, seals and filling equipment are washed and sterilized prior to use. This process allows for large scale tilling operations consistent with the volumes produced from the 2000 L fermentation.
• the formulation buffer about 10 mM phosphate, about 140 mM NaCl, pH 6.0 ⁇ 0.5, about 0.02% polysorbate 80, can be compounded in a Class 10,000 suite and used to dilute the bulk drug product to the final concentration. In-process specifications of concentration, pH and density are preferably reached prior to filtration.
• the formulated natalizumab or other immunoglobulin can be sterile filtered through a 0.2 ⁇ m Millipak filter into a stainless steel surge tank inside the sterile core. Filling, stoppering and capping of natalizumab is fully automated. In-process samples for bulk sterility are collected; fill weight and headspace testing is conducted throughout the filling operation. Filled drug product is stored under refrigeration at about 2-8° C.
• Filling occurs within a fully validated Class 100 sterile core.
• the filling line is validated to provide fill volumes within expected tolerances for the 5.0 mL and 20 mL fill volumes.
• Comprehensive environmental monitoring is conducted throughout the filling operation and reviewed to verify continual compliance with this standard.
• Media fills are conducted on a quarterly basis to support aseptic filling operations.
• the 200 L drug substance material produced can be bottled pursuant to the following example. Vials, filling needles, the filtration assembly and tubing are prepared and sterilized prior to use. Stoppers can be prepared by the supplier. The stoppers are then sterilized prior to filling.
• Natalizumab drug product or other protein is filled on a semi-automatic filling line, with batch preparation of components, automated filling, immediate stoppering, and a subsequent capping operation. This operation is appropriate for small batch scale operations.
• the final bulk solution is then sterile filtered through a 0.2 ⁇ m Millipak filter into a sterile glass receiving vessel within a Class 100 environment. Regular calibration and in-process checks ensure that the filling tolerance remains within ⁇ 2%. Vials are stoppered and capped immediately. Filled drug product is preferably stored refrigerated at 2-8° C.
• the glass receiving vessel can be any number of vials, but can for example be a 5.0 or 20 mL neutral glass vial Type I (EP) supplied by, for example, Epsom Glass or AMILCO or a 5.0 mL or 20 mL USP Type I borosilicate glass vial, supplied by, for example Kimble or Wheaton.
• EP neutral glass vial Type I
• Vial closures include, but are not limited to a 13 mm Helvoet Pharma V9145/FM 157/1 grey butyl rubber stopper or a 13 mm and 20 mm Helvoet Pharma V9145/FM 157/1 grey butyl rubber stopper or a 13 mm or 20 mm West 4432/50 gray butyl rubber stopper.
• the rubber-stoppered bottled is then sealed most typically using an aluminum seal, such as that manufactured by West.
• the typical method of administering natalizumab is intravenous. Intravenous administration requires the final formulation to be isotonic.
• a formulation of AN100226 (natalizumab), 5 mg/mL in 50 mM L-histidine, 150 mM NaCl, pH 6.0 was initially chosen (Formulation #1).
• Polysorbate 80 was introduced into the formulation (Formulation #2) to resolve the observed protein precipitation.
• the polysorbate for use with the present invention is low in peroxide, i.e., polysorbate from Sigma, Product number P6479, Lot Number 071K7283.
• the two factors that have been shown to accelerate the precipitation of the AN100226 antibody are the presence of trace levels of silicone oil and denaturation at the air-liquid interface.
• the silicone oil was introduced into the product upon use of standard lubricated polypropylene syringes equipped with siliconized rubber stoppers. The introduction of the silicone oil is sufficient to cause discernible antibody precipitation in Formulation # 1 upon gentle agitation and room temperature storage.
• the aggregation, deamidation and subsequent precipitation caused by denaturation at the air-liquid interface has become more discernable problematic with the drug being shipped to more clinical sites. Both causes of protein precipitation have been resolved by the addition of polysorbate 80 at a concentration of 0.02% (w/v).
• Formulation #2 shows comparable stability to the histidine/NaCl formulation (Formulation #1) in all protein characterization assays, while providing increased stability during product shipping and handling in the clinical setting.
• polysorbate 80 to the formulation also overcomes the problem of precipitating or aggregating antibody when preparing formulations with higher protein content.
• Initial work focused on agitation-induced aggregation at high protein concentrations, including 50 mg/mL.
• SEC-HPLC size exclusion-high performance liquid chromatography
• the size exclusion HPLC method used to monitor antibody aggregation was modified to increase sensitivity for detection of the trace impurities by increasing the column load 5-fold to 100 ⁇ L, and the sample is applied undiluted rather than 10-fold diluted.
• the absorbency is monitored at 260 nm to reflect the absorbency maximum of the impurities. The method provides a tool to evaluate the presence of these trace impurities in both placebo and product, as the antibody emerges much earlier in the elution profile.
• Placebo and natalizumab final drug product formulated in Formulations #1 and #2 were analyzed by the SEC-HPLC method described above. Analysis of the placebo in Formulation #1 spiked with polysorbate 80 to 0.02% (w/v) was performed just prior to chromatography. This shows the UV absorbency of polysorbate 80, histidine, and salt in the absence of the trace impurities. The broad peak at 16 minutes is associated with polysorbate 80 while the peaks at approximately 26-27 minutes are attributed to histidine and salt. The histidine/NaCl/0.02% (w/v) polysorbate 80 placebo (Formulation #2) stored at 5° C. for two months shows a marked increase in the late eluting peaks which implicates polysorbate 80 in the production of these impurities. In addition, the eluting at 16 minutes disappeared, indicating that the polysorbate 80 has been degraded.
• AN100226 stored as bulk drug substance for approximately 5 months at 5° C. in Formulation #1 was analyzed after spiking with polysorbate 80 to 0.02% (w/v) just prior to chromatography. The antibody elutes at 16-18 minutes using these overload conditions. The remainder of the profile resembles the placebo with polysorbate 80 spike.
• the two-month stability samples for natalizumab lot #AN100226-0004 were also analyzed by this method.
• the elution profile for the 5° C. natalizumab sample indicates the absence of any additional peaks and comparable levels of the histidine/salt peaks at 26-27 minutes.
• the trace impurities are detected at two months for the 25° C. sample, and elevated levels are present for the two month 40° C. sample. Thus, these impurities have not been detected in the clinical supplies, which are stored at 5° C. The appearance of these trace impurities is occurring much more rapidly in placebo than in natalizumab.
• histidine was replaced with inorganic buffering components in the placebo formulation.
• the placebo product for the clinical trials is a sterile isotonic phosphate buffered solution with 0.02% (w/v) polysorbate 80 at pH 6.0.
• the substitution of histidine with phosphate was demonstrated to significantly reduce the rate of polysorbate 80 degradation.
• 100 ⁇ L of the phosphate/NaCl/0.02% (w/v) polysorbate 80 placebo formulation was analyzed by size exclusion HPLC monitored at 260 nm both at time zero and after 3 days at 60° C. Little change is seen in the SEC-HPLC profile as a result of this incubation.
• the SEC-HPLC profile for the histidine/NaCl/0.02% (w/v) polysorbate 80 formulation following only two days at 60° C. shows significant levels of trace impurities related to the degradation of polysorbate 80.
• the SEC-HPLC profiles for 100 ⁇ L injections of samples used in the mouse single-dose limit test were determined.
• the natalizumab sample in Formulation #1 spiked with polysorbate 80 prior to analysis has little 260 nm absorbing material eluting after 20 minutes. The peak eluting at 34 minutes was found in this lot of natalizumab without polysorbate 80 addition and therefore does not indicate polysorbate 80 degradation.
• the placebo in Formulation #2 stored at 40° C. for six weeks showed complete degradation, as the total area under the curve was 12.8 million ⁇ V.seconds.
• the natalizumab sample in Formulation #2 and stored at 40° C. for six weeks had less complete degradation.
• the analysis confirms that the samples stored at 40° C. and tested in the mouse single-dose limit test are laden with degraded polysorbate 80.
• Formulation #2 was heated to 60° C. for 3 days in the presence of a needle to convert all the polysorbate 80 to the maximum levels of impurities. The reaction was confirmed to have degraded all the polysorbate 80 by both SEC and reverse phase HPLC. This material was diluted one-to-one with a 10 mg/mL solution of AN100226 in Formulation #2 resulting in a solution containing 0.01% (w/v) polysorbate 80 and 50% of the maximum level of degraded polysorbate 80. These antibody solutions were exposed to both shaking and siliconized syringes for several hours; aggregation of the antibody was prevented. The control samples exposed to the same conditions but without polysorbate 80 showed significant precipitation.
• IEF isoelectric focusing
• a preliminary limit for these trace impurities in natalizumab has been established based on the mouse single-dose limit test, the antibody solubility data with 50% degraded polysorbate 80, and estimates of the extent of the polysorbate 80 degradation. The method has been included in the ongoing stability program and a limit has been established. If additional lots are manufactured with histidine buffer, these limits will be applied at time of release as well.
• Adjust pH to 6.0 ⁇ 0.5 with phosphoric acid Optimally store formulation at about 5° C. to about 8° C.
• Additional liquid formulations of antibody at high concentration may consist of phosphate or other suitable buffer (such as histidine, citrate, acetate or succinate) in the concentration range of 2 to 50 mM, to provide buffering in the pH range of 3.0 to 7.0. Most preferably, the pH is 6.0, ⁇ 0.5.
• phosphate or other suitable buffer such as histidine, citrate, acetate or succinate
• the pH is 6.0, ⁇ 0.5.
• polyols such as sorbitol and mannitol
• disaccharides such as sucrose or trehalose
• amino acids such as glycine
• surfactants such but not limited to the polysorbates, add stability when used in the range of 0.001 to 2%.
• natalizumab was concentrated to 65 mg/mL in 10 mM sodium phosphate, 140 mM sodium chloride, pH 6, with about 0.06% polysorbate 80.
• the resulting solution was slightly opalescent but without particulates.
• the sample contained greater than 99% monomer with no high molecular weight aggregate or low molecular weight species by SEC.
• a stable lyophilized pharmaceutical formulation is provided. Because phosphate buffer undergoes a pH change during freezing, it is necessary to replace the phosphate with a different buffer.
• This buffer may be comprised of histidine, citrate or succinate,with the ability to buffer effectively in the pH range of 3.0 to 7.0, most preferably in the range of 6.0 ⁇ 0.5.
• polyols such as mannitol
• sugars such as sucrose
• polyols may be used alone or in a combination to provide for stability and adjustment of the tonicity.
• amino acids such as glycine
• at levels of 10-1000 mM may be used to prevent aggregation.
• Surfactants such as polysorbates or poloxamers, may be used at levels from 0.001% to 2.0% to provide for stability before lyophilization and after reconstitution and to provide for more rapid reconstitution times.
• the protein following the final purification step, may be formulated using ultrafiltration for concentration and diafiltration for buffer exchange.
• the protein may also be formulated using column chromatography for buffer exchange. Some combination of these techniques may also be used.
• the final desired protein concentration may be obtained by filling at a protein and excipient concentration lower than desired and reconstitution at a smaller volume.
• a 2.5 mL fill volume of a 40 mg/mL solution may be used, followed by reconstitution with 1 mL to obtain a 100 mg/mL solution.
• natalizumab at a concentration of 20 mg/mL, was lyophilized in a solution containing 5 mM histidine, 20 mg/mL sucrose and 0.02% polysorbate 80, pH 6.
• the solution was filled at 5mL per vial into 10 mL borosilicate glass vials and fitted with gray butyl rubber lyophilization stoppers. Lyophilization was done using a Virtis Gensis model lyophilizer.
• the product was frozen at a shelf temperature of ⁇ 60° C. for 10 hours and then the shelf temperature was raised to ⁇ 40°.
• Primary drying was performed at a shelf temperature of ⁇ 10° C. and a chamber pressure of 100 mTorr for 20 hours. Secondary drying was achieved at a shelf temperature of 25° C. with a chamber pressure of 100 mTorr for 10 hours.
• the vials were stoppered under vacuum.
• the vials were then reconstituted using 1 mL of sterile WFI to give a formulation containing 100 mg/mL natalizumab.
• the samples were analyzed immediately after lyophilization and after 2 wks of storage in the lyophilized form at 40 deg. In both cases reconstitution times were immediate.
• the reconstituted solutions were clear and colorless with an absence of particulate material.
• the samples contained greater than 99% monomer by SEC, with no high molecular weight aggregate, or low molecular weight species. After 2 weeks storage at 40 deg, the sample showed 94% potency relative to reference (specification 80-125%).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Rheumatology (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Inorganic Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Physical Education & Sports Medicine (AREA)
• Neurosurgery (AREA)
• Nutrition Science (AREA)
• Pain & Pain Management (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=32869424

Family Applications (7)

Family Applications After (6)

Country Status (29)

Cited By (42)

Families Citing this family (70)

Citations (2)

Family Cites Families (26)

• 2004
  • 2004-02-09 TR TR2018/08801T patent/TR201808801T4/tr unknown
  • 2004-02-09 MX MXPA05008409A patent/MXPA05008409A/es active IP Right Grant
  • 2004-02-09 DK DK18174115.8T patent/DK3417875T3/da active
  • 2004-02-09 ZA ZA200506159A patent/ZA200506159B/en unknown
  • 2004-02-09 SI SI200432441T patent/SI2236154T1/en unknown
  • 2004-02-09 CN CN201210292453.7A patent/CN103040732B/zh not_active Expired - Lifetime
  • 2004-02-09 SI SI200432502T patent/SI3417875T1/sl unknown
  • 2004-02-09 EP EP18174115.8A patent/EP3417875B1/en not_active Expired - Lifetime
  • 2004-02-09 AU AU2004210679A patent/AU2004210679A1/en not_active Abandoned
  • 2004-02-09 MY MYPI20040377A patent/MY162623A/en unknown
  • 2004-02-09 SK SK5067-2005A patent/SK50672005A3/sk not_active Application Discontinuation
  • 2004-02-09 KR KR1020057014654A patent/KR20050110628A/ko active Search and Examination
  • 2004-02-09 JP JP2006503453A patent/JP4728948B2/ja not_active Expired - Lifetime
  • 2004-02-09 CL CL200400224A patent/CL2004000224A1/es unknown
  • 2004-02-09 US US10/773,406 patent/US20050053598A1/en not_active Abandoned
  • 2004-02-09 PT PT181741158T patent/PT3417875T/pt unknown
  • 2004-02-09 NO NO20054164A patent/NO346070B1/no unknown
  • 2004-02-09 CA CA2515444A patent/CA2515444C/en not_active Expired - Lifetime
  • 2004-02-09 EP EP10005235.6A patent/EP2236154B1/en not_active Expired - Lifetime
  • 2004-02-09 DK DK10005235.6T patent/DK2236154T3/en active
  • 2004-02-09 WO PCT/US2004/003873 patent/WO2004071439A2/en active Application Filing
  • 2004-02-09 EP EP20180019.0A patent/EP3777880A1/en active Pending
  • 2004-02-09 HU HUE18174115A patent/HUE051878T2/hu unknown
  • 2004-02-09 EP EP04709508A patent/EP1592440A4/en not_active Withdrawn
  • 2004-02-09 RU RU2005128280/15A patent/RU2358763C2/ru active IP Right Revival
  • 2004-02-09 CN CN2004800094412A patent/CN1771053B/zh not_active Expired - Lifetime
  • 2004-02-09 ES ES18174115T patent/ES2819011T3/es not_active Expired - Lifetime
  • 2004-02-09 PT PT100052356T patent/PT2236154T/pt unknown
  • 2004-02-10 TW TW093103043A patent/TWI367766B/zh not_active IP Right Cessation
  • 2004-02-10 UY UY28184A patent/UY28184A1/es not_active Application Discontinuation
  • 2004-02-10 PE PE2004000149A patent/PE20050190A1/es active IP Right Grant
  • 2004-02-10 AR ARP040100411A patent/AR043144A1/es unknown
  • 2004-09-02 UA UAA200508632A patent/UA82685C2/uk unknown
• 2005
  • 2005-08-01 IL IL170008A patent/IL170008A/en active IP Right Grant
• 2009
  • 2009-10-02 US US12/572,978 patent/US8349321B2/en not_active Expired - Lifetime
• 2010
  • 2010-06-01 AU AU2010202254A patent/AU2010202254B2/en not_active Expired
  • 2010-12-13 JP JP2010277365A patent/JP2011088913A/ja active Pending
• 2012
  • 2012-09-06 US US13/605,590 patent/US8900577B2/en not_active Expired - Lifetime
  • 2012-11-14 US US13/676,866 patent/US8815236B2/en not_active Expired - Lifetime
• 2013
  • 2013-08-12 HK HK13109421.5A patent/HK1182021A1/xx not_active IP Right Cessation
  • 2013-09-17 JP JP2013192276A patent/JP2014028831A/ja not_active Withdrawn
• 2014
  • 2014-10-27 US US14/524,687 patent/US20150044206A1/en not_active Abandoned
• 2018
  • 2018-03-07 US US15/914,980 patent/US10954303B2/en not_active Expired - Lifetime
  • 2018-06-29 CY CY20181100682T patent/CY1120574T1/el unknown
• 2020
  • 2020-09-15 CY CY20201100869T patent/CY1123667T1/el unknown
• 2021
  • 2021-03-03 US US17/191,589 patent/US20210292419A1/en active Pending

Patent Citations (2)

Also Published As

Similar Documents

Legal Events